At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products.

We are a specialty pharmaceutical company with one approved proprietary product, SUMAVEL™ DosePro™ (sumatriptan injection) needle-free delivery system and one proprietary product candidate in late-stage development for the treatment of central nervous system disorders and pain. SUMAVEL DosePro enables subcutaneous delivery of sumatriptan without a needle for the acute treatment of migraine attacks, with or without aura, and cluster headache episodes. We received approval from the FDA in July 2009 for SUMAVEL DosePro. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. We have initiated Phase 3 development for ZX002.

Manufacturing
Sumavel™ DosePro™

A behind-the-scenes look of how SUMAVEL DosePro is manufactured. It delivers fast acting therapy that patients can self-administer in three easy steps. Watch the video

SUMAVEL™ DosePro™

SUMAVEL DosePro utilizes our proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the treatment of acute migraine and cluster headache. Sumavel DosePro is a fast acting therapy that patients can self-administer in three easy steps. Click here to learn more.

For full prescribing information, click here.